Compare · MYO vs ZBH
MYO vs ZBH
Side-by-side comparison of Myomo Inc. (MYO) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYO and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $17.34B, about 342.6x MYO ($50.6M).
- Over the past year, MYO is down 46.2% and ZBH is down 5.7% - ZBH leads by 40.4 points.
- ZBH has been more active in the news (15 items in the past 4 weeks vs 11 for MYO).
- ZBH has more recent analyst coverage (25 ratings vs 3 for MYO).
- Company
- Myomo Inc.
- Zimmer Biomet Holdings Inc.
- Price
- $1.55+17.42%
- $89.39-0.27%
- Market cap
- $50.6M
- $17.34B
- 1M return
- +87.18%
- +12.31%
- 1Y return
- -46.18%
- -5.74%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- AMEX
- NYSE
- IPO
- 2017
- News (4w)
- 11
- 15
- Recent ratings
- 3
- 25
Myomo Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest MYO
- Chief Commercial Officer Mitchell Micah covered exercise/tax liability with 6,529 shares, decreasing direct ownership by 6% to 102,949 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry covered exercise/tax liability with 7,635 shares, decreasing direct ownership by 7% to 100,983 units (SEC Form 4)
- Chief Financial Officer Henry David A covered exercise/tax liability with 10,050 shares, decreasing direct ownership by 2% to 435,124 units (SEC Form 4)
- Director Kirk Thomas F bought $50,803 worth of shares (40,002 units at $1.27), increasing direct ownership by 6% to 693,865 units (SEC Form 4)
- Amendment: Chief Commercial Officer Mitchell Micah sold $77,689 worth of shares (90,231 units at $0.86), decreasing direct ownership by 45% to 109,478 units (SEC Form 4)
- Director Kirk Thomas F bought $24,825 worth of shares (25,000 units at $0.99), increasing direct ownership by 4% to 653,863 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry sold $32,239 worth of shares (32,000 units at $1.01), decreasing direct ownership by 23% to 108,618 units (SEC Form 4)
- SEC Form SD filed by Myomo Inc.
- Director Kirk Thomas F bought $68,243 worth of shares (75,006 units at $0.91), increasing direct ownership by 14% to 628,863 units (SEC Form 4)
- Director Manko Joseph M. Jr. bought $173,908 worth of MYO (201,197 units at $0.86) (SEC Form 4)
Latest ZBH
- SEC Form 4 filed by Officer Noor Jehanzeb
- Group President, Asia Pacific Yi Sang sold $413,216 worth of shares (5,000 units at $82.64), decreasing direct ownership by 16% to 27,251 units (SEC Form 4)
- Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SD filed by Zimmer Biomet Holdings Inc.
- SEC Form 4 filed by Director Farrell Michael J.
- SEC Form 4 filed by Director Bernard Betsy J
- SEC Form 4 filed by Director Hilado Maria Teresa
- SEC Form 4 filed by Director Shapiro Louis
- SEC Form 4 filed by Director Kurdikar Devdatt